Literature DB >> 24461673

Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP).

Arash Ronaghy1, Robert D Streilein1, Russell P Hall2.   

Abstract

Entities:  

Keywords:  Auto-antibodies: IgG subclass; Bullous pemphigoid; Rituximab

Mesh：

Substances：

Year:  2013        PMID： 24461673     DOI： 10.1016/j.jdermsci.2013.11.014

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN： 0923-1811            Impact factor:   4.563


× No keyword cloud information.
  4 in total

Review 1.  IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.

Authors:  Maartje G Huijbers; Jaap J Plomp; Silvère M van der Maarel; Jan J Verschuuren
Journal:  Ann N Y Acad Sci       Date:  2018-01-28       Impact factor: 5.691

Review 2.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

Review 3.  Bullous pemphigoid.

Authors:  Denise Miyamoto; Claudia Giuli Santi; Valéria Aoki; Celina Wakisaka Maruta
Journal:  An Bras Dermatol       Date:  2019-05-09       Impact factor: 1.896

4.  Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies.

Authors:  Luca Petricca; Maria Rita Gigante; Annamaria Paglionico; Stefano Costanzi; Gisella Vischini; Clara Di Mario; Valentina Varriano; Giacomo Tanti; Barbara Tolusso; Stefano Alivernini; Giuseppe Grandaliano; Gianfranco Ferraccioli; Elisa Gremese
Journal:  Front Med (Lausanne)       Date:  2020-10-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.